Stock Price Movement and Market Context
On 24 Nov 2025, Epigral's share price touched an intraday low of Rs.1428, marking its lowest level in the past year. This represents a decline of 2.08% during the trading session, with the stock underperforming its sector by 0.78%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,343.57, a gain of 0.13%. The index remains close to its 52-week high of 85,801.70, just 0.54% away, supported by a three-week consecutive rise and leadership from mega-cap stocks. The Sensex is also positioned above its 50-day moving average, which itself is above the 200-day moving average, signalling a generally bullish market environment.
Long-Term and Recent Performance Analysis
Epigral's stock has experienced a return of -26.32% over the last year, contrasting with the Sensex's positive 7.85% return over the same period. The stock's 52-week high was Rs.2195.85, highlighting the extent of the recent decline. Over the past five years, the company's operating profit has shown a compound annual rate of -5.49%, indicating subdued growth in core profitability.
Recent quarterly results have also reflected challenges. The company's interest expenses for the latest six months stood at Rs.45.21 crores, representing a growth of 286.41%. Meanwhile, the quarterly profit after tax (PAT) was Rs.51.22 crores, down by 52.6% compared to the average of the previous four quarters. The operating profit to net sales ratio for the quarter was recorded at 22.53%, the lowest in recent periods, suggesting margin pressures.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Comparative Sector and Valuation Metrics
Despite the recent price decline, Epigral demonstrates certain financial strengths. The company reports a return on capital employed (ROCE) of 23.19%, indicating efficient use of capital relative to earnings. Its debt servicing capacity is supported by a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels.
Valuation metrics show an enterprise value to capital employed ratio of 2.6, which is considered fair within the Specialty Chemicals sector. The stock is trading at a discount relative to its peers' historical valuations. Over the past year, while the stock price has declined by over a quarter, the company's profits have risen by 37.1%, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.5, which may indicate undervaluation based on earnings growth.
Shareholding and Market Position
Epigral's majority shareholding is held by promoters, reflecting concentrated ownership. The company operates within the Specialty Chemicals industry, a sector that has experienced mixed performance amid evolving market conditions. The stock's recent underperformance relative to the BSE500 index over the last three years, one year, and three months highlights ongoing challenges in maintaining competitive returns.
Is Epigral your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Financial Indicators
Epigral's financial indicators present a mixed picture. The company’s operating profit growth rate over five years is negative, while recent quarterly results show a significant rise in interest expenses and a decline in net profit. The operating profit margin for the latest quarter is at its lowest point, which may be a factor in the stock’s price movement.
Conversely, the company’s capital efficiency and debt metrics remain relatively strong, with a high ROCE and low leverage. The valuation ratios suggest the stock is trading at a discount compared to peers, despite the recent price decline. These factors contribute to the current market assessment of Epigral within the Specialty Chemicals sector.
Market Outlook and Broader Context
While Epigral’s stock has reached a 52-week low, the broader market environment remains positive. The Sensex’s proximity to its 52-week high and its recent gains reflect investor confidence in large-cap stocks and the overall market trend. Epigral’s underperformance relative to the Sensex and its sector peers underscores the challenges faced by the company in aligning with broader market momentum.
Investors and market participants may continue to monitor Epigral’s financial results and sector developments to assess the stock’s positioning within the Specialty Chemicals industry.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
